NASDAQ:MDCX Medicus Pharma Q3 2025 Earnings Report $0.33 -0.01 (-4.25%) As of 04:00 PM Eastern ProfileEarnings HistoryForecast Medicus Pharma EPS ResultsActual EPS-$0.65Consensus EPS -$0.38Beat/MissMissed by -$0.27One Year Ago EPSN/AMedicus Pharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMedicus Pharma Announcement DetailsQuarterQ3 2025Date11/14/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Medicus Pharma Earnings HeadlinesMedicus Pharma Advances SkinJect and Teverelix Amid Financing Gains and Going-Concern Risk3 hours ago | tipranks.comMedicus Pharma (MDCX) Projected to Post Quarterly Earnings on MondayAugust 9 at 2:10 AM | americanbankingnews.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.August 12 at 1:00 AM | Stansberry Research (Ad)Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United KingdomAugust 3, 2026 | globenewswire.comMedicus Pharma targets Gorlin Syndrome with SkinJect - ICYMIAugust 1, 2026 | proactiveinvestors.comMedicus Pharma Gets UAE Approval to Begin Phase 2 Endometriosis Drug trialJuly 31, 2026 | finance.yahoo.comSee More Medicus Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Medicus Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Medicus Pharma and other key companies, straight to your email. Email Address About Medicus PharmaMedicus Pharma (NASDAQ:MDCX), Inc., traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer. Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies. Its research and development efforts are centered on expanding a pipeline that includes additional oncology supportive care candidates as well as treatments aimed at acute neurological and critical conditions. The company partners with established contract manufacturers and distributors to facilitate efficient production and market access. Medicus Pharma primarily serves the U.S. market through a network of specialty pharmacies and hospital systems and is evaluating opportunities for international distribution. Led by a management team with experience in specialty pharmaceuticals, regulatory affairs and commercial operations, the company remains focused on advancing its pipeline and delivering targeted support therapies for patients undergoing cancer treatment and acute care interventions.View Medicus Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not DemandCoreWeave's $129 Billion AI Backlog Changes the Bull CaseGE Vernova’s AI Power Boom Faces a Profit TestCardinal Health Earnings: Can Perfection Get Priced In Twice?Legacy Jet Builders Stall While Embraer Accelerates to New HighsFastly’s Q2 Rally Shows Investors Are Buying the Edge AI TurnaroundA Westinghouse IPO Could Reset the Nuclear Stock Conversation Upcoming Earnings Brookfield (8/13/2026)NU (8/13/2026)Applied Materials (8/13/2026)BHP Group (8/17/2026)Palo Alto Networks (8/17/2026)Home Depot (8/18/2026)Medtronic (8/18/2026)Keysight Technologies (8/18/2026)Lowe's Companies (8/19/2026)TJX Companies (8/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
